SCHEMBL2144177

SCHEMBL2144177

C[Si](Cl)(Cl)CCc1ccccc1CCl

nearest known ligand 0.34

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.32
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
TAAR1 Q96RJ0 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1033573 0.91 TAAR1 (0.34) ALDH1A1MTNR1AMTNR1BTAAR1
SCHEMBL4849033 0.88 ALDH1A1 (0.34) ALDH1A1TSHRKMT2AMTNR1AMTNR1B
SCHEMBL8718608 0.83 HPGD (0.38) ALDH1A1MTNR1AMTNR1B
SCHEMBL7534967 0.83 GABRA1 (0.37) ALDH1A1MTNR1AMTNR1BTAAR1
SCHEMBL3224942 0.83 ALDH1A1 (0.36) ALDH1A1TSHRKMT2ATAAR1
SCHEMBL11848934 0.82 ALDH1A1 (0.33) ALDH1A1TSHRKMT2AMTNR1AMTNR1B
SCHEMBL6580961 0.79 KMT2A (0.33) ALDH1A1TSHRKMT2A
SCHEMBL3339281 0.79 MTNR1A (0.33) ALDH1A1TSHRKMT2AMTNR1AMTNR1B
SCHEMBL15544091 0.78 TAAR1 (0.34) ALDH1A1MTNR1AMTNR1BTAAR1
SCHEMBL19064354 0.77 ALDH1A1 (0.31) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1985645-B1 Low molecular weight siloxanes with one functional group GELEST INC (US) 2017-03-15 EP disclosed
US-8455599-B2 Asymmetric low molecular weight siloxanes with one functional group GELEST TECHNOLOGIES, INC. (US) 2013-06-04 US disclosed
EP-2345686-A2 Low molecular weight siloxanes with one functional group GELEST, INC. (US) 2011-07-20 EP disclosed
US-20100298591-A1 ASYMMETRIC LOW MOLECULAR WEIGHT SILOXANES WITH ONE FUNCTIONAL GROUP GELEST, INC. (US) 2010-11-25 US disclosed
US-7799888-B2 Low molecular weight siloxanes with one functional group GELEST, INC. (US) 2010-09-21 US disclosed
EP-1428795-B1 SILSESQUIOXANE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF CHISSO CORP (JP) 2009-07-22 EP disclosed
US-7463400-B1 Electrochromic display device FUJI XEROX CO., LTD. (JP) 2008-12-09 US disclosed
US-7449539-B2 Silsesquioxane derivative and production process for the same CHISSO CORPORATION (JP) 2008-11-11 US disclosed
US-20080269429-A1 LOW MOLECULAR WEIGHT SILOXANES WITH ONE FUNCTIONAL GROUP GELEST, INC. (US) 2008-10-30 US disclosed
EP-1985645-A2 Low molecular weight siloxanes with one functional group GELEST, INC. (US) 2008-10-29 EP disclosed
EP-0970066-A1 AMINOEPOXIDES FROM AMINOALDEHYDES AND IN-SITU FORMED HALOMETHYL ORGANOMETALLIC REAGENT G.D. SEARLE & CO. (US) 2000-01-12 EP disclosed
US-5872299-A Method of preparing intermediates for retroviral protease inhibitors G. D. SEARLE & CO. (US) 1999-02-16 US disclosed
US-5872298-A Method of preparing intermediates for retroviral protease inhibitors G. D. SEARLE & CO. (US) 1999-02-16 US disclosed
EP-0855388-A2 Method for making intermediates useful in synthesis of retroviral protease inhibitors G.D. SEARLE & CO. (US) 1998-07-29 EP disclosed
WO-1998029401-A1 AMINOEPOXIDES FROM AMINOALDEHYDES AND IN-SITU FORMED HALOMETHYL ORGANOMETALLIC REAGENT G.D. SEARLE & CO. (US) 1998-07-09 WO disclosed
US-5648511-A Method for making intermediates useful in the synthesis of retroviral protease inhibitors G.D. SEARLE & CO. (US) 1997-07-15 US disclosed
US-5583238-A Method for making intermediates useful in synthesis of retroviral protease inhibitors G. D. SEARLE & CO. (US) 1996-12-10 US disclosed
EP-0730570-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1996-09-11 EP disclosed
EP-0641333-B1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS SEARLE & CO (US) 1996-08-14 EP disclosed
WO-1995014653-A1 METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1995-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298591-A1 ASYMMETRIC LOW MOLECULAR WEIGHT SILOXANES WITH ONE FUNCTIONAL GROUP ILK, LASP1, PCNA ALDH1A1 2527/4885TSHR 3911/4885KMT2A 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.